OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC

The placebo effect in oncology trials and the criteria for approving drugs

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML

Comment: POLAR gene profile can identify which patients can safely avoid radiation therapy after breast-conserving surgery

Updates from TAILORx and RxPONDER: Implications for practice

Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease